Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.
Epistemonikos ID: 00539459043769814bb016373bd8f035fb72d2a8
First added on: May 15, 2024